1. NCI Press Office. NCI issues clinical announcement on cervical cancer: chemotherapy plus radiation improves survival [Internet]. Bethesda, MD: National Institutes of Health (NIH);2015. cited 2015 Nov 10. Available from:
http://www.nih.gov/news/pr/feb99/nci-22.htm.
3. Rose PG. Chemoradiotherapy for cervical cancer. Eur J Cancer. 2002; 38:270–278.
4. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev. 2010; (1):CD008285.
5. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008; 26:5802–5812.
6. Mazeron R, Gilmore J, Dumas I, Champoudry J, Goulart J, Vanneste B, et al. Adaptive 3D image-guided brachytherapy: a strong argument in the debate on systematic radical hysterectomy for locally advanced cervical cancer. Oncologist. 2013; 18:415–422.
7. Pötter R, Georg P, Dimopoulos JC, Grimm M, Berger D, Nesvacil N, et al. Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol. 2011; 100:116–123.
8. Teh J, Yap SP, Tham I, Sethi VK, Chua EJ, Yeo R, et al. Concurrent chemoradiotherapy incorporating high-dose rate brachytherapy for locally advanced cervical carcinoma: survival outcomes, patterns of failure, and prognostic factors. Int J Gynecol Cancer. 2010; 20:428–433.
9. Mazeron R, Castelnau-Marchand P, Dumas I, del Campo ER, Kom LK, Martinetti F, et al. Impact of treatment time and dose escalation on local control in locally advanced cervical cancer treated by chemoradiation and image-guided pulsed-dose rate adaptive brachytherapy. Radiother Oncol. 2015; 114:257–263.
10. Parker K, Gallop-Evans E, Hanna L, Adams M. Five years’ experience treating locally advanced cervical cancer with concurrent chemoradiotherapy and high-dose-rate brachytherapy: results from a single institution. Int J Radiat Oncol Biol Phys. 2009; 74:140–146.
11. Chen SW, Liang JA, Hung YC, Yeh LS, Chang WC, Lin WC, et al. Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications. Int J Radiat Oncol Biol Phys. 2006; 66:1370–1377.
12. Toita T, Kitagawa R, Hamano T, Umayahara K, Hirashima Y, Aoki Y, et al. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule. Gynecol Oncol. 2012; 126:211–216.
13. Haie-Meder C, Pötter R, Van Limbergen E, Briot E, De Brabandere M, Dimopoulos J, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol. 2005; 74:235–245.
14. Dimopoulos JC, Pötter R, Lang S, Fidarova E, Georg P, Dörr W, et al. Dose-effect relationship for local control of cervical cancer by magnetic resonance image-guided brachytherapy. Radiother Oncol. 2009; 93:311–315.
15. Ariga T, Toita T, Kasuya G, Nagai Y, Inamine M, Kudaka W, et al. External beam boost irradiation for clinically positive pelvic nodes in patients with uterine cervical cancer. J Radiat Res (Tokyo). 2013; 54:690–696.
16. Wakatsuki M, Ohno T, Kato S, Ando K, Noda SE, Kiyohara H, et al. Impact of boost irradiation on pelvic lymph node control in patients with cervical cancer. J Radiat Res (Tokyo). 2014; 55:139–145.
17. Hata M, Koike I, Miyagi E, Numazaki R, Asai-Sato M, Kasuya T, et al. Radiation therapy for pelvic lymph node metastasis from uterine cervical cancer. Gynecol Oncol. 2013; 131:99–102.
18. Rash DL, Lee YC, Kashefi A, Durbin-Johnson B, Mathai M, Valicenti R, et al. Clinical response of pelvic and para-aortic lymphadenopathy to a radiation boost in the definitive management of locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2013; 87:317–322.
19. Vargo JA, Kim H, Choi S, Sukumvanich P, Olawaiye AB, Kelley JL, et al. Extended field intensity modulated radiation therapy with concomitant boost for lymph node-positive cervical cancer: analysis of regional control and recurrence patterns in the positron emission tomography/computed tomography era. Int J Radiat Oncol Biol Phys. 2014; 90:1091–1098.
20. Grigsby PW, Singh AK, Siegel BA, Dehdashti F, Rader J, Zoberi I. Lymph node control in cervical cancer. Int J Radiat Oncol Biol Phys. 2004; 59:706–712.
21. Kasuya G, Toita T, Furutani K, Kodaira T, Ohno T, Kaneyasu Y, et al. Distribution patterns of metastatic pelvic lymph nodes assessed by CT/MRI in patients with uterine cervical cancer. Radiat Oncol. 2013; 8:139.
22. Niibe Y, Kazumoto T, Toita T, Yamazaki H, Higuchi K, Ii N, et al. Frequency and characteristics of isolated para-aortic lymph node recurrence in patients with uterine cervical carcinoma in Japan: a multi-institutional study. Gynecol Oncol. 2006; 103:435–438.
23. Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol. 2010; 40:107–111.
24. Niibe Y, Kenjo M, Kazumoto T, Michimoto K, Takayama M, Yamauchi C, et al. Multi-institutional study of radiation therapy for isolated para-aortic lymph node recurrence in uterine cervical carcinoma: 84 subjects of a population of more than 5,000. Int J Radiat Oncol Biol Phys. 2006; 66:1366–1369.
25. Yap ML, Cuartero J, Yan J, Pintilie M, Fyles A, Levin W, et al. The role of elective para-aortic lymph node irradiation in patients with locally advanced cervical cancer. Clin Oncol (R Coll Radiol). 2014; 26:797–803.
26. Tangjitgamol S, Katanyoo K, Laopaiboon M, Lumbiganon P, Manusirivithaya S, Supawattanabodee B. Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer. Cochrane Database Syst Rev. 2014; 12:CD010401.
27. ClinicalTrials.gov. Cisplatin and radiation therapy with or without carboplatin and paclitaxel in patients with locally advanced cervical cancer [Internet]. Bethesda, MD: National Library of Medicine (NLM) at National Institutes of Health (NIH);2015. cited 2015 Nov 10. Available from:
https://clinicaltrials.gov/ct2/show/NCT01414608.
28. Niibe Y, Chang JY. Novel insights of oligometastases and oligo-recurrence and review of the literature. Pulm Med. 2012; 2012:261096.
29. Iwata S, Yonemoto T, Iizasa T, Niibe Y, Kamoda H, Ishii T. Oligo-recurrence of osteosarcoma patients: treatment strategies for pulmonary metastases. Ann Surg Oncol. 2015; 06. 20. [Epub]. DOI:
10.1245/s10434-015-4682-1.